UroGen Pharma Hits New 52-Week High of $41.91, Up 222% Yearly

UroGen Pharma has reached a significant milestone by hitting a new 52-week high of USD 41.91 on July 20, 2026. This achievement marks a notable increase from its 52-week low of USD 15.04, reflecting a remarkable one-year performance of 222.0%. In comparison, the S&P 500 has shown a performance of 18.21% during the same period, highlighting UroGen Pharma's strong position within the Pharmaceuticals and Biotechnology industry. With a market capitalization of USD 836 million, UroGen Pharma is classified as a small-cap company. The firm has demonstrated impressive financial metrics, including a return on equity of 145.53%. However, it is important to note that the company is currently loss-making, as indicated by the absence of a price-to-earnings ratio and a dividend yield of 0.00%. The debt-to-equity ratio stands at -0.02, suggesting a unique financial structure. Overall, UroGen Pharma's recent performance underscores its dynamic presence in the market.